INNT
TOTAL INVALIDATION PROCESSED BY THE IB
10/24/2022
Back to search
Official data from USPTO
DAWNRAYS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
38
Latest update
04/07/2023
Trademark type
Combined
Nice classes
5
Filing date
04/27/2010
Registration date
06/14/2011
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/31/2021
Last transaction
04/07/2023
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
3
Owner type
03
Owner location
CN
Examiner
JUN, WON KYUNG WENDY
Law office
L30
Current location
GENERIC WEB UPDATE
Mark description
The mark consists of the wording "DAWNRAYS". To the left of the wording is a design element of a circle superimposed over a shaded rectangle.
Holders and representatives
Holders
Suzhou Dawnrays Pharmaceutical Co., Ltd.
Representatives
SUZHOU DAWNRAYS PHARMACEUTICAL CO., LTD.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Chemical preparations for pharmaceutical purposes for the treatment of the nervous system diseasesthe immune system diseasesthe cardio-vascular system diseasesthe metabolic system diseasesthe respiratory system diseasesthe digestive system diseasesthe circulatory system diseasesthe urinary system diseasesthe endocrine system diseasesthe blood system diseasesskin disordersgynecological diseasesophthalmic diseasesmental disordersinflammatory disordersliver diseasestumor and deficiency diseases; Pharmaceutical preparations for injection for the treatment of the nervous system diseasesthe immune system diseasesthe cardio-vascular system diseasesthe metabolic system diseasesthe respiratory system diseasesthe digestive system diseasesthe circulatory system diseasesthe urinary system diseasesthe endocrine system diseasesthe blood system diseasesskin disordersgynecological diseasesophthalmic diseasesmental disordersinflammatory disordersliver diseasestumor and deficiency diseases; Pharmaceutical preparations in tablet form for the treatment of the nervous system diseasesthe immune system diseasesthe cardio-vascular system diseasesthe metabolic system diseasesthe respiratory system diseasesthe digestive system diseasesthe circulatory system diseasesthe urinary system diseasesthe endocrine system diseasesthe blood system diseasesskin disordersgynecological diseasesophthalmic diseasesmental disordersinflammatory disordersliver diseasestumor and deficiency diseases; Raw material medicines for the treatment of the nervous system diseasesthe immune system diseasesthe cardio-vascular system diseasesthe metabolic system diseasesthe respiratory system diseasesthe digestive system diseasesthe circulatory system diseasesthe urinary system diseasesthe endocrine system diseasesthe blood system diseasesskin disordersgynecological diseasesophthalmic diseasesmental disordersinflammatory disordersliver diseasestumor and deficiency diseases; Chemico-pharmaceutical preparations for the treatment of the nervous system diseasesthe immune system diseasesthe cardio-vascular system diseasesthe metabolic system diseasesthe respiratory system diseasesthe digestive system diseasesthe circulatory system diseasesthe urinary system diseasesthe endocrine system diseasesthe blood system diseasesskin disordersgynecological diseasesophthalmic diseasesmental disordersinflammatory disordersliver diseasestumor and deficiency diseases; Chemical preparations for medical purposes for the treatment of the nervous system diseasesthe immune system diseasesthe cardio-vascular system diseasesthe metabolic system diseasesthe respiratory system diseasesthe digestive system diseasesthe circulatory system diseasesthe urinary system diseasesthe endocrine system diseasesthe blood system diseasesskin disordersgynecological diseasesophthalmic diseasesmental disordersinflammatory disordersliver diseasestumor and deficiency diseases; Prepared traditional Chinese medicines for the treatment of respiratory system diseasesdigestive system diseasesliver diseasescardio-vascular system diseases and nervous system diseases; Medicines for the treatment of the nervous system diseasesthe immune system diseasesthe cardio-vascular system diseasesthe metabolic system diseasesthe respiratory system diseasesthe digestive system diseasesthe circulatory system diseasesthe urinary system diseasesthe endocrine system diseasesthe blood system diseasesskin disordersgynecological diseasesophthalmic diseasesmental disordersinflammatory disordersliver diseasestumor and deficiency diseases in humans; Medicines in capsule form for the treatment of the nervous system diseasesthe immune system diseasesthe cardio-vascular system diseasesthe metabolic system diseasesthe respiratory system diseasesthe digestive system diseasesthe circulatory system diseasesthe urinary system diseasesthe endocrine system diseasesthe blood system diseasesskin disordersgynecological diseasesophthalmic diseasesmental disordersinflammatory disordersliver diseasestumor and deficiency diseases
Publications
History of USPTO decisions and trademark events.
38 publications found
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
09/26/2022
INPC
INVALIDATION PROCESSED
09/26/2022
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
08/31/2022
C71T
CANCELLED SECTION 71
12/31/2021
RNWL
INTERNATIONAL REGISTRATION RENEWED
05/14/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/17/2020
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - MAILED
04/07/2017
71AG
REGISTERED-SEC.71 ACCEPTED
04/06/2017
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
03/21/2017
PR71
POST REGISTRATION ACTION MAILED - SEC.71
03/09/2017
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
03/06/2017
ES71
TEAS SECTION 71 RECEIVED
09/20/2016
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/20/2016
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
02/26/2013
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/27/2011
FIMP
FINAL DISPOSITION PROCESSED
09/27/2011
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/14/2011
R.PR
REGISTERED-PRINCIPAL REGISTER
06/14/2011
PUBO
PUBLISHED FOR OPPOSITION
03/29/2011
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/10/2011
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/10/2011
NPUB
NOTICE OF PUBLICATION
03/09/2011
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
02/24/2011
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/17/2011
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/15/2011
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/15/2011
ALIE
ASSIGNED TO LIE
02/07/2011
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/31/2011
RFNT
REFUSAL PROCESSED BY IB
09/19/2010
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/24/2010
MAFR
APPLICATION FILING RECEIPT MAILED
08/24/2010
RFRR
REFUSAL PROCESSED BY MPU
08/23/2010
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/23/2010
CNRT
NON-FINAL ACTION WRITTEN
08/22/2010
DOCK
ASSIGNED TO EXAMINER
08/20/2010
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/20/2010
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/19/2010
Continuous trademark protection
Get notified about every new filing that threatens DAWNRAYS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.